Before the Discovery of HAART By Mark Harrington And we are here as on a darkling plain Swept with confused alarms of struggle and flight, Where ignorant armies clash by night. —Matthew Arnold, “Dover Beach”[i] This is the second in…
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
In 2012, the Fulbright Association presented its J. William Fulbright Prize for International Understanding to Médecins Sans Frontières (MSF); the first time this was awarded to an organization, not an individual. Treatment Action Group’s executive director, Mark Harrington, delivered this…
On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.
TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.
Over 3,500 people with HIV are on waiting lists for lifesaving antiretroviral drugs. Many more lack access because of other funding cuts and program restrictions. Congress and President Barack Obama must act now to make sure all persons with HIV…
By Mark Harrington On September 30, 2010 the U.S. National Institutes of Health (NIH) became the first research funder to license intellectual property rights to the Medicines Patent Pool essential to manufacturing anti-HIV protease inhibitors. The patent pool is an…
By Coco Jervis and Sue Perez Over the last few years, G8 and other national leaders have lamented that health care systems in poor countries are inadequate to keep pregnant women, mothers, babies, and children healthy and that universal access…
By Richard Jefferys and Scott Morgan In July of this year, the stubborn persistence and commitment of microbicide researchers, advocates, and trial participants was finally rewarded with positive results from a South African trial of the gel form of the…